pharmaphorum2d
Veru shares plunge despite positive data in obesity trial
The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...
Veru Inc.’s Promising Phase IIb Results Suggest Investment Opportunity with Enobosarm’s Weight Management Potential
William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...
Oppenheimer maintains Veru stock Outperform rating, $5 target
Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...
BioWorld3d
Akero’s EFX reverses cirrhosis in MASH patients in phase IIb trial
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). Top-line data of the phase ...
Veru's experimental drug helps older obese patients on Wegovy preserve muscle
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December
The Chicago Fed National Activity Index rose to 0.15 in December, recording the strongest reading in seven months, and versus ...
Veru Reports Positive Data From Phase 2b QUALITY Study
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company Monday announced positive topline results from the Phase 2b ...
FierceBiotech3d
Veru's drug conserves muscle mass for older patients taking Novo's Wegovy in phase 2 trial
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
BioWorld4d
Veru weight loss study hits primary endpoint, stock drops
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). The side effect of lean mass ...
Oppenheimer maintains Veru stock Outperform rating as trial nears
Oppenheimer reiterated an Outperform rating on Veru Inc. (NASDAQ:VERU), which has seen remarkable momentum with a 200% return over the past year and a 96% gain year-to-date. Anticipation is building ...